A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer

Trial Profile

A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Anastrozole; Everolimus; Exemestane; Fulvestrant; Letrozole; LY 3023414; Tamoxifen; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jul 2017 Planned End Date changed from 16 Dec 2018 to 1 Dec 2019.
    • 07 Jul 2017 Planned primary completion date changed from 16 Dec 2018 to 1 Dec 2019.
    • 04 Apr 2017 Planned End Date changed from 1 Jun 2018 to 16 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top